Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2016 - 2021)

  • ID: 3784691
  • Report
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 4


  • Amgen Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline
  • Janssen Biotech Inc.
  • Novartis AG
  • Seattle Genetics
  • MORE
The Global Cancer Monoclonal Antibodies Market was valued at USD 27 billion for the year 2015, and is expected to grow at a CAGR of around 8-15% from 2015 to 2020. Cancer is a severe disease, which starts from a single cell; cancer genetically transforms a normal cell into a tumor cell. Gradually, it spreads to more cells. There is no one definite cause for cancer. The interaction between a person’s genetic factor and other external agents (physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, and biological carcinogens) can roughly be cited as the major cause. In 2012, WHO reported 14 million new cancer cases and 8.2 million deaths due to cancer. The most common types of cancer that caused death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and esophageal cancer. There is a steady rise and incidence of cancer annually. Drugs haven’t been able to provide complete cure for any cancer. Moreover, all these drugs available for cancer as chemotherapeutic agents have adverse side-effects because the drugs tend to affect the normal, healthy cells along with the cancerous cells. Hence, there is huge amount of research and development going on all over the world to combat this deadly disease.

Monoclonal antibodies are specifically cloned antibodies that have the capability to identify cancer cells, bind to proteins on their surface and simulate an immune response. Due to their specificity, they are expected and have been proved to lessen the adverse effects of cancer to a much higher level. Most major pharmaceutical companies are investing for research on monoclonal antibodies. The drug research companies have also collaborated with many academics and institutions like National Institutes of Health, USA, National Cancer Institute, USA and many others for research and development of cancer drugs/ monoclonal antibodies. Due to the highly customizable nature of monoclonal antibodies, various organizations, research institutes and companies are using it as a tool to target various cancers.

The global monoclonal antibody market has been segmented based on:

- Therapeutic application
- Breast,
- Liver
- Blood
- Brain
- Colorectal
- Hodgkins and non-hodgkins lymphoma
- leukemia
- Others
- Types of monoclonal antibodies
- Murine antibodies
- Chimeric and humanized antibodies
- Fully humanized antibodies
- Conjugated cancer therapies using monoclonal antibodies
- Immunoliposome
- Radioimmunotherapy
- Immunocytokines

Avastin, Rituxan, Bexxar, Kadcyla, Erbitux, Arzerra, Yervoy, Adcetris, Herceptin are some of the well-marketed monoclonal antibodies. A large patient population, severity of the disease, unavailability of good drugs and side effects of the existing drugs are the main reasons for the big void in the monoclonal antibodies market for new entrants to fill in. With only few monoclonal antibodies in the market exclusively for cancer therapies, there is always a good prospect for a new entrant. Conjugated therapies, using monoclonal antibodies, have been observed to give better results compared to stand alone treatment. Currently, there is a trend towards more research in conjugated therapies. With growing collaborations with institutes and companies, a very good market is expected in the near future. North America has the largest market for cancer monoclonal antibodies. India, China and Australia are expected to have a large market in the near future.

The key players in this market are Amgen, Bristol Meyer Squibb, GlaxoSmithKline, Roche, Eli Lilly, ImmunoGen, Novartis, Genmab and others.


- Large global patient pool
- Severity of the disease
- Unavailability of completely curing drugs
- Side effects of the existing drugs
- More specificity of monoclonal antibodies in targeting cancer cells


- Stringent regulatory guidelines
- Long duration of research and development
- Long duration of clinical trials
- High cost for research and development

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
Note: Product cover images may vary from those shown
2 of 4


  • Amgen Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline
  • Janssen Biotech Inc.
  • Novartis AG
  • Seattle Genetics
  • MORE
1. Introduction
1.1 Study deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast period years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Senario
5.2 Cancer Monoclonal antibody Applications
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value chain analysis
5.6 product Life cycle analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter's Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat to new entrants
5.9.4 Threat to substitute products and services
5.9.5 Competitive Rivalry within the industry
6. Drivers, Restraints, Opportunities
6.1 Market Drivers
6.1.1 Large global patient population
6.1.2 Severity of the disease with chronic nature
6.1.3 Side effects of existing drugs/ therapy
6.1.4 Specificity of Monoclonal antibodies
6.2 Market Restraints
6.2.1 Stringent Regulatory guidelines
6.3 Key Challenges
6.3.1 High Research and development cost
6.3.2 Longer duration of R&D and Clinical Trials
7. Market Segmentation
7.1 By Application
7.1.1 Breast Cancer
7.1.2 Non-small cell Lung cancer
7.1.3 Neuroblastoma
7.1.4 Melanoma
7.1.5 Gastric cancer
7.1.7 Hodgkin Lymphoma
7.1.8 Malignant ascites
7.1.9 Colorectal cancer
7.1.10 non-Hodgkin Lymphoma
7.1.11 Brain Tumor
7.1.12 Lymphocytic Leukemia
7.1.13 Ovarian cancer
7.1.14 Others
7.2 By types of Monoclonal Antibodies
7.2.1 Murine Antibodies
7.2.2 Chimeric and Humaized Antibodies
7.2.3 Fully Humanized antibodies
7.3 By Conjugated Cancer therapies using Monoclonal Antibodies
7.3.1 Immunoliposomes
7.3.2 Radioimmunotherapy
7.3.3 Antibody directed enzyme prodrug therapy
7.3.4 Immunotoxins
7.3.5 Immunocytokines
7.3.6 Others
8. Market segmentation by Geography - Regional Share and forecast
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Rest of North America
8.2 Europe
8.2.1 Introduction
8.2.2 Germany
8.2.3 United Kingdom
8.2.4 France
8.2.5 Italy
8.2.6 Spain
8.2.7 Russia
8.2.8 Rest of Europe
8.3 Asia-Pacific (APAC)
8.3.1 Introduction
8.3.2 China
8.3.3 Japan
8.3.4 India
8.3.5 Australia
8.3.6 South Korea
8.3.7 Rest of Asia Pacific
8.4 Middle-East and Africa
8.4.1 Introduction
8.4.2 UAE
8.4.3 Saudi Arabia
8.4.4 Israel
8.4.5 Rest of Middle-east & Africa
8.5 Latin America
8.5.1 Introduction
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Mexico
8.5.5 Rest of Latin America
9. Competitive Landscape
9.1 Merger and acquisition analysis
9.2 Patent Analysis
9.3 The Challenges
10. Key Vendor Analysis
10.1 Amgen Inc.
10.2 Bristol-Meyer Squibb
10.3 GlaxoSmithKline
10.4 Roche Holding
10.5 Spectrum Pharmaceuticals
10.6 Merck & Co. Inc.
10.7 Eli Lilly & co.
10.8 ImmunoGen Inc.,
10.9 Seattle Genetics
10.10 Janssen Biotech Inc.
10.11 Genmab
10.12 Novartis AG
11. Analyst outlook for Investment opportunities
12. Future Outlook of the market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Amgen Inc.
  • Bristol-Meyer Squibb
  • GlaxoSmithKline
  • Roche Holding
  • Spectrum Pharmaceuticals
  • Merck & Co. Inc.
  • Eli Lilly & Co.
  • ImmunoGen Inc.
  • Seattle Genetics
  • Janssen Biotech Inc.
  • Genmab
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown